Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
75%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Other(1)

Detailed Status

Recruiting2
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

unknown125%
recruiting250%
completed125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingnot_applicable

Genomic Study of Cutis Tricolor

NCT06073171
recruitingnot_applicable

Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid

NCT06479018
unknown

Borrelia Species in Cutaneous Lyme Borreliosis

NCT00576082
completednot_applicable

Development of the Tool " iPSC " for the Functional Study of Mutations Responsible for Mental Retardation

NCT02980302

Clinical Trials (4)

Showing 4 of 4 trials
NCT06073171Not Applicable

Genomic Study of Cutis Tricolor

Recruiting
NCT06479018Not Applicable

Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid

Recruiting
NCT00576082

Borrelia Species in Cutaneous Lyme Borreliosis

Unknown
NCT02980302Not Applicable

Development of the Tool " iPSC " for the Functional Study of Mutations Responsible for Mental Retardation

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4